{"id":2522,"date":"2025-12-12T16:07:42","date_gmt":"2025-12-12T09:07:42","guid":{"rendered":"https:\/\/naviva.com.vn\/?p=2522"},"modified":"2025-12-25T16:56:31","modified_gmt":"2025-12-25T09:56:31","slug":"key-updates-in-the-who-guidelines-for-varicella-vaccines","status":"publish","type":"post","link":"https:\/\/naviva.com.vn\/en\/key-updates-in-the-who-guidelines-for-varicella-vaccines","title":{"rendered":"Key Updates in the WHO Guidelines for Varicella Vaccines"},"content":{"rendered":"<p><span style=\"font-weight: 400; font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\">The World Health Organization (WHO) has recently released an updated guideline for varicella vaccines, replacing the previous 2014 version.<\/span><\/p>\n<p><a href=\"https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4.png\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-2427\" src=\"https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4.png\" alt=\"\" width=\"3924\" height=\"2900\" srcset=\"https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4.png 3924w, https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4-300x222.png 300w, https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4-648x479.png 648w, https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4-768x568.png 768w, https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4-1600x1182.png 1600w, https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4-160x118.png 160w\" sizes=\"auto, (max-width: 3924px) 100vw, 3924px\" \/><\/a><\/p>\n<p><span style=\"font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\"><span style=\"font-weight: 400;\">The document provides updated global guidance on <\/span><a href=\"https:\/\/naviva.com.vn\/en\/product\/barycela-inj-live-attenuated-varicella-vaccine\"><span style=\"font-weight: 400;\">varicella vaccination<\/span><\/a><span style=\"font-weight: 400;\">, emphasizing the use of a two-dose vaccination schedule to achieve optimal immunity. It also validates the inclusion of a new vaccine strain, MAV\/06, developed by GC Biopharma (South Korea), and allows for interchangeability between vaccines containing this strain and those using the commonly used Oka strain.<\/span><\/span><\/p>\n<p><span style=\"font-weight: 400; font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\">At the same time, the guideline supports the inclusion of vaccines containing this new strain in national immunization programs in regions with a high disease burden, as part of comprehensive disease control strategies.<\/span><\/p>\n<h2><span style=\"font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\"><b>Key Updates and Recommendations in the Guideline<\/b><\/span><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\"><span style=\"font-weight: 400;\">Validation of a new vaccine strain: The guideline confirms that the MAV\/06 strain (used in GC Biopharma\u2019s BARYCELA vaccine) is equivalent to the Oka strain, helping to expand global vaccine supply and enabling its integration into existing immunization schedules.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\"><span style=\"font-weight: 400;\">Two-dose vaccination schedule: While a single dose provides good protection, the guideline emphasizes that two doses produce a more durable and optimal immune response. This standard schedule has already been adopted in several countries, including the United Kingdom.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\"><span style=\"font-weight: 400;\">Public health strategy:<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><span style=\"font-weight: 400;\"> The guideline reaffirms that varicella vaccination is the primary intervention for reducing severe disease and complications, and supports the introduction of varicella vaccines into Expanded Program on Immunization (EPI) schedules for children in regions where varicella remains a major public health concern.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\"><span style=\"font-weight: 400;\">Replacement of the 2014 guideline: The new document updates the 2014 recommendations by incorporating new scientific evidence and global implementation experience.<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<\/ul>\n<h2><span style=\"font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\"><b>WHO Validation of the MAV\/06 Varicella Vaccine Strain<\/b><\/span><\/h2>\n<p><span style=\"font-weight: 400; font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\">The MAV\/06 varicella vaccine strain developed by GC Biopharma has been officially validated in the WHO Position Paper on Varicella Vaccines:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\"><span style=\"font-weight: 400;\">Formally recognized by WHO as a standard varicella vaccine strain alongside the widely used Oka strain<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\"><span style=\"font-weight: 400;\">Interchangeability between strains is validated, strengthening global vaccine supply security and ensuring continuity of immunization programs<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\"><span style=\"font-weight: 400;\">The MAV\/06 strain was officially included in the WHO Position Paper on varicella vaccination published on 21 November 2025<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400; font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\">The WHO Position Paper on Vaccines serves as a globally endorsed reference for immunization policy, developed by the Strategic Advisory Group of Experts on Immunization (SAGE).<\/span><\/p>\n<p><span style=\"font-weight: 400; font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\">With its inclusion in the WHO guideline, BARYCELA Inj., GC Biopharma\u2019s varicella vaccine containing the MAV\/06 strain, has achieved international recognition as equivalent to Oka strain\u2013based varicella vaccines.<\/span><\/p>\n<p><span style=\"font-weight: 400; font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\">WHO has also confirmed the interchangeability between MAV\/06- and Oka-based varicella vaccines, allowing BARYCELA Inj. to be administered alongside existing varicella vaccines within a two-dose immunization schedule. BARYCELA Inj. is therefore regarded as a validated alternative vaccine in the global varicella vaccine market.<\/span><\/p>\n<p><span style=\"font-weight: 400; font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\">The safety and immunogenicity of the MAV\/06 strain have been demonstrated in Phase III clinical trials of BARYCELA Inj. and published in reputable international scientific journals. These studies show robust immune responses and a favorable safety profile, supporting the vaccine\u2019s inclusion in national immunization programs.<\/span><\/p>\n<p><span style=\"font-weight: 400; font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\">The validation of this new strain contributes to a more flexible global vaccine supply system by enabling strain interchangeability, thereby reducing the risk of supply shortages and improving supply continuity.<\/span><\/p>\n<p><span style=\"font-weight: 400; font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\">Ms. Jaewoo Lee, Head of Regulatory Science and Product Development at GC Biopharma, stated: \u201cThe inclusion of the MAV\/06 strain in the WHO guideline for varicella vaccines marks a significant milestone in strengthening the global supply of varicella vaccines.<\/span><\/p>\n<p><span style=\"font-weight: 400; font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\">With our proven manufacturing capacity and strong international supply capabilities, we are committed to supporting global immunization efforts by ensuring reliable access to high-quality vaccines.\u201d<\/span><\/p>\n<p><span style=\"font-weight: 400; font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\">The MAV\/06 strain, independently developed by GC Biopharma in 1993, has been used for nearly 30 years in products such as Suduvax, Varicella, and most recently BARYCELA Inj.<\/span><\/p>\n<p><span style=\"font-weight: 400; font-size: 14pt; font-family: 'times new roman', times, serif; color: #000000;\">In Vietnam, NAVIVA Group is the authorized distributor and supplier of BARYCELA Inj., the varicella vaccine containing the MAV\/06 strain.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-size: 12pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400; color: #000000;\">Source: <\/span><a href=\"https:\/\/tuoitre.vn\/cac-diem-moi-cap-nhat-trong-ban-huong-dan-cua-who-cho-vac-xin-thuy-dau-20251212083945517.htm?gidzl=5ULv4hTcC2aO-d4JjNqqBHx_THIhU35_K_ya5l0lR2jIhIb3-djhVLAjB4RwA3fuKgzuHJcRid0Dls0zAW\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Tuoi Tre Newspaper<\/span><\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The World Health Organization (WHO) has recently released an updated guideline for varicella vaccines, replacing the previous 2014 version. The document provides updated global guidance on varicella vaccination, emphasizing the use of a two-dose vaccination schedule to achieve optimal immunity. It also validates the inclusion of a new vaccine strain, MAV\/06, developed by GC Biopharma [&hellip;] <\/p>\n","protected":false},"author":4,"featured_media":2427,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[25],"tags":[],"class_list":["post-2522","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/2522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/comments?post=2522"}],"version-history":[{"count":4,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/2522\/revisions"}],"predecessor-version":[{"id":2527,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/2522\/revisions\/2527"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/media\/2427"}],"wp:attachment":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/media?parent=2522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/categories?post=2522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/tags?post=2522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}